No needles needed: All-oral therapy options for relapsed and refractory multiple myeloma.

Author: FranzJoseph, MyrusElizabeth, RichterJoshua, SanchezLarysa

Paper Details 
Original Abstract of the Article :
Immense progress has been made for the treatment of multiple myeloma over the past two decades, with patient outcomes improving dramatically as a result. Patient quality of life, however, is constantly challenged by complications of the disease, side effects of therapy and the overall burden receivi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/j.blre.2022.100993

データ提供:米国国立医学図書館(NLM)

Multiple Myeloma: Oral Therapy Options for Relapsed and Refractory Disease

Multiple myeloma is a type of blood cancer that affects plasma cells. Despite significant advances in treatment, relapsed and refractory multiple myeloma remain a challenge. This article reviews the current and investigational oral therapy options for these patients, emphasizing the benefits of all-oral regimens in terms of convenience and quality of life.

Oral Therapy for Multiple Myeloma: A Convenient and Effective Option

The article highlights the benefits of all-oral regimens in managing relapsed and refractory multiple myeloma. It provides a comprehensive overview of available and investigational oral therapies, organized by the degree of prior treatment. The article also discusses challenges such as renal insufficiency and cytopenias, highlighting strategies for managing these complications.

Navigating the Desert of Multiple Myeloma: Finding Hope in Oral Therapies

This article provides a valuable resource for understanding the current landscape of oral therapy options for multiple myeloma. It emphasizes the importance of personalized treatment approaches, considering factors such as prior drug refractoriness, disease biology, and patient-specific considerations. By staying informed about the latest advancements in oral therapy, patients and healthcare professionals can work together to navigate the challenges of relapsed and refractory multiple myeloma with greater confidence.

Dr.Camel's Conclusion

Multiple myeloma can be a formidable desert of challenges, but research continues to uncover new ways to manage this disease. The advent of oral therapies offers a beacon of hope for patients seeking effective and convenient treatment options. By embracing personalized approaches and staying informed about the latest advancements, we can work together to create a more supportive and empowering environment for those living with multiple myeloma.

Date :
  1. Date Completed 2023-01-27
  2. Date Revised 2023-02-16
Further Info :

Pubmed ID

36137842

DOI: Digital Object Identifier

10.1016/j.blre.2022.100993

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.